## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigion,	D.C.	20049

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	nd Address of atrick Y	Reporting Person				Biotech							ck all applica	ıble)	g Perso	in(s) to Issue 10% Owi		
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/06/2024								Officer ( below)	give title		Other (sp below)	ecify	
C/O SANA BIOTECHNOLOGY, INC. 188 EAST BLAINE STREET, SUITE 400					4. If Amendment, Date of Original Filed (Month/Day/Year) 06/07/2024					Line)	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person							
(Street) SEATTL	E W	⁄A	98102								Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Ta	able I - Non-I	Derivat	ive S	ecuritie	s Acc	quired, l	Disp	osed o	f, or Be	neficially	Owned					
Date				Transact ate lonth/Day	Execution Date,		Date,	Code (Instr.			Securities Beneficial Owned Fo		Form:	Direct Ir Indirect B tr. 4)	. Nature of ndirect Beneficial Ownership			
								Code	v	Amount	(A) o	Price	Reported Transaction(s) (Instr. 3 and 4)			(1	Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Exec (Month/Day/Year) if any	3A. Deemed Execution Date, if any (Month/Day/Year	4. Transa Code (	action (Instr.	Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)		Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (Right to Buy)	\$7.36	06/06/2024		A		65,000 <sup>(1)</sup>		(2)	0	6/05/2034	Common Stock	65,000(1)	\$0.00	65,000	) <sup>(1)</sup>	D		

## **Explanation of Responses:**

- 1. This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired.
- 2. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date

## Remarks:

/s/ Julie Shah, Attorney-in-Fact for Patrick Y. Yang

\*\* Signature of Reporting Person Date

07/15/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.